AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20808854
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) and L-carnitine for 6 months
Trial: 20808854
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) and L-carnitine for 12 months (post-hoc analysis)
Trial: 20808854
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (VPA and L-carnitine)
Trial: 20808854
Drug: Age factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age factor in treatment
Trial: 7600115
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (2 IU.m‐2.d‐1)
Trial: 7600115
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor-I (80 micrograms.kg‐1.d‐1)
Trial: 2145790
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (A) alone
Trial: 2145790
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (A) plus ipratropium bromide (IB)
Trial: 25925992
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg plus UFH
Trial: 24120550
Drug: HIV-v (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-v (250 μg or 500 μg, either alone or adjuvanted with ISA-51)
Trial: 24120550
Drug: HIV-v (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-v (high adjuvanted dose)
Trial: 19808134
Drug: Roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 300 mg once daily for 3 months
Trial: 19808134
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 3 months
Trial: 11116754
Drug: Clarithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (250 mg) co-administered with tolbutamide (500 mg)
Trial: 11116754
Drug: Tolbutamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide (500 mg) alone
Trial: 8371129
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg iv loading dose followed by 1 mg/hour continuous infusion for the treatment period)
Trial: 8371129
Drug: Chlorpromazine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (60 mg/m2/day by continuous infusion for the same period, maximum 8 days)
Trial: 17196413
Drug: Theophylline treatment
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline treatment (0.2g, orally, q 12h for 1 month)
Trial: 7767539
Drug: Theophylline treatment
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline treatment
Trial: 10705222
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no theophylline treatment)
Trial: 10333620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cimetidine and levamisole (group B)
Trial: 8600545
Drug: rhIL-3 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-3 (2.5 or 5.0 microg/kg/d) administered by subcutaneous injection for either 5 or 10 days following ABMT.
Trial: 8600545
Drug: rhGM-CSF (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF (250 microg/m2/d as a 2-hour intravenous infusion) administered 24 hours after the last dose of rhIL-3.
Trial: 8600545
Drug: Sequential cytokine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential cytokine therapy (rhIL-3 and rhGM-CSF) post-ABMT.
Trial: 9008458
Drug: Verapamil 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 480 mg
Trial: 3297230
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg)
Trial: 26309133
Drug: Full-mouth non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth non-surgical treatment (FM-SRP)
Trial: 19564319
Drug: Therapeutic allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic allopurinol (500 mg intravenously)
Trial: 16972973
Drug: Intravenous frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous frusemide 2 mg/kg
Trial: 8329287
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg racemic ibuprofen (RAC)
Trial: 8329287
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (S)-ibuprofen (S-IBU)
Trial: 25546356
Drug: Gut microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbiota metabolism
Trial: 19787380
Drug: Infusion set
RxNorm normalized name: INFUSION SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion set (500-cc solution bag with gravity-driven delivery)
Trial: 19787380
Drug: Infusion pump
RxNorm normalized name: Infusion Pump 50cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion pump
Trial: 15937041
Drug: Transdermal secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal secretin applied daily in ointment form for 4 weeks
Trial: 15937041
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied daily in ointment form for 4 weeks
Trial: 10987150
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (active and passive jaw movement exercises, correction of body posture, and relaxation techniques)
Trial: 8988067
Drug: Watercress +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watercress + Acetaminophen
Trial: 1455306
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution subcutaneously every 8 hours
Trial: 1455306
Drug: Octreotide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide and Saline solution
Trial: 26959482
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 3 1,000 IU daily for 6 months
Trial: 25149431
Drug: Modified vaccinia
RxNorm normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified vaccinia Ankara (MVA) vaccine administered by subcutaneous injection at Week 0 and 4
Trial: 25149431
Drug: Modified vaccinia
RxNorm normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified vaccinia Ankara (MVA) vaccine
Trial: 22240180
Drug: Intraoperative music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative music added to routine pain control measures (ibuprofen and paracervical block)
Trial: 22240180
Drug: Routine pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine pain control measures only (ibuprofen and paracervical block)
Trial: 20416451
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg oral tablets daily for one month
Trial: 17687689
Drug: cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine 10 mg/day
Trial: 17687689
Drug: doxepine 10
RxNorm normalized name: doxepin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxepine 10 mg/day
Trial: 17687689
Drug: hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyzine 25 mg/day
Trial: 9495433
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg/kg) administered 1 min before intubation
Trial: 9495433
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg/kg) administered 3 min before intubation
Trial: 9495433
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg/kg) administered 5 min before intubation
Trial: 9495433
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg/kg) administered 10 min before intubation
Trial: 2668060
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days treatment with amoxycillin (1.5 g/day)
Trial: 2668060
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days therapy (750 mg amoxycillin/day)
Trial: 1213890
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with estrogen in an alcoholic vehicle (0.05% dienestroldiacetate) applied daily on the scalp skin
Trial: 1213890
Drug: Corresponding preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding preparation without estrogen (control group)
Trial: 1213890
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with estrogen
Trial: 31091575
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose remifentanil (Group L)
Trial: 31091575
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose remifentanil (Group H)
Trial: 31091575
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose remifentanil with gradual withdrawal (Group G)
Trial: 25520333
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention protocol (manual tooth/gum brushing plus 0.12% chlorhexidine oral rinse, twice per day, plus upright positioning during feeding)
Trial: 21777835
Drug: Intercoat gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercoat gel (polyethylene oxide-sodium carboxymethylcellulose) applied intrauterinely during hysteroscopic surgery
Trial: 27999118
Drug: Oral Contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptives (OCs)
Trial: 12116891
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg caplets and i.v. argatroban 1.5 micrograms/kg/min
Trial: 12116891
Drug: Lidocaine 2
RxNorm normalized name: lidocaine 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2 mg/kg/hr and i.v. argatroban 1.5 micrograms/kg/min
Trial: 12116891
Drug: Oral digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral digoxin 0.375 mg/day and i.v. argatroban 2 micrograms/kg/min
Trial: 11206232
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 microg twice daily
Trial: 9525449
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 microg once daily
Trial: 7712753
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (parenteral cefotaxime, oral and enteral polymyxin E, amphotericin B, tobramycin)
Trial: 7960687
Drug: nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 300 mg
Trial: 363631
Drug: Mazindol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (2 mg/day)
Trial: 23748458
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy at a dose of 4 J/cm²
Trial: 23748458
Drug: Needling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needling with 2% lidocaine injection
Trial: 8172700
Drug: VT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT with medication
Trial: 8172700
Drug: VT without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VT without medication
Trial: 30862667
Drug: JT010 (TRPA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JT010 (TRPA1 agonist)
Trial: 30862667
Drug: A-967079 (TRPA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-967079 (TRPA1 antagonist)
Trial: 25807891
Drug: Rapid Syllable
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Syllable Transition (ReST) treatment
Trial: 23943468
Drug: Continuous antiretroviral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antiretroviral therapy (ART)
Trial: 12538746
Drug: Cyclosporine treatment
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine treatment for 24 weeks
Trial: 12224599
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 24 weeks
Trial: 11142481
Drug: Alternating regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating regimen of bolus and continuous infusion 5-FU (200 mg/m2 continuous infusion) + weekly bolus 6-S-leucovorin (20 mg/m2)
Trial: 11142481
Drug: Control arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm: biweekly cycles of MTX (200 mg/m2 on day 1) followed by bolus 5-FU (600 mg/m2 on day 2) + 6-S-leucovorin rescue
Trial: 9095423
Drug: Once-daily wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily wound cleansing and dressing change
Trial: 9095423
Drug: Twice-daily dressing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dressing changes (Control)
Trial: 8242966
Drug: Subcutaneous apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous apomorphine (mean optimal dose of 2.7 mg)
Trial: 9856921
Drug: Intravenous procainamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procainamide
Trial: 3728294
Drug: Intravenous quinidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinidine
Trial: 26527417
Drug: A4250 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A4250 3 mg/day
Trial: 26527417
Drug: A4250 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A4250 1.5 mg twice daily
Trial: 26527417
Drug: A4250 0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A4250 0.1, 0.3, 1, 3, or 10 mg (single administration)
Trial: 19094432
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil (0.3 - 0.6 microg/kg per min)
Trial: 19094432
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (5 - 10 microg/kg per h)
Trial: 15663590
Drug: Live lactobacilli
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live lactobacilli in combination with low dose oestriol (Gynoflor)
Trial: 7872940
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment in a subgroup of 40 patients
Trial: 24796714
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health educational program (90-min every 2 weeks for 3 months)
Trial: 24796714
Drug: General information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General information about oral health (control group)
Trial: 21640779
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given simultaneously
Trial: 21640779
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given 30 days apart
Trial: 21640779
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine
Trial: 19120333
Drug: Medium-dose UVA1
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UVA1 phototherapy
Trial: 16829185
Drug: Levosimendan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (12 microg/kg followed by a continuous infusion of 0.1-0.2 microg/min)
Trial: 15054439
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g taurine daily for 8 weeks
Trial: 3520132
Drug: Minoxidil, 2.5
RxNorm normalized name: Minoxidil, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil, 2.5 mg twice daily (n = 12)
Trial: 3520132
Drug: Captopril, 25
RxNorm normalized name: Captopril, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 25 mg twice daily (n = 11)
Trial: 31733985
Drug: Inhaler drug
RxNorm normalized name: Inspirease Inhaler Drug Delivery Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler drug education
Trial: 31733985
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhaler drug education)
Trial: 21749847
Drug: Midodrine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine plus standard medical therapy
Trial: 20632084
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg/month (approved dose)
Trial: 20632084
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg plus loading dose (500 mg on day 0, 250 mg on days 14, 28, and monthly thereafter)
Trial: 20632084
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (high dose)
Trial: 18517289
Drug: Paroxetine 10
RxNorm normalized name: PARoxetine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 10 mg
Trial: 10548902
Drug: Orlistat 3
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 3 x 120 mg/day
Trial: 8527701
Drug: Roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate 150 mg
Trial: 2337212
Drug: 0.2 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 or 0.3 mg/kg diltiazem 60 seconds before laryngoscopy
Trial: 28033561
Drug: Aspirin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (10 days of intake)
Trial: 28033561
Drug: Aspirin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin resistance tests (PFA‐200, VerifyNow®, TXB2)
Trial: 26273264
Drug: Chlorhexidine (CHX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX), amoxicillin (AMX) 500 mg, metronidazole (MET) 250 mg
Trial: 28463028
Drug: Oral naproxen
RxNorm normalized name: naproxen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naproxen
Trial: 21435642
Drug: Administration at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration at fixed intervals
Trial: 17825135
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol 800 microg
Trial: 31183514
Drug: Pertuzumab 840
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab 840 mg intravenous plus trastuzumab and chemotherapy
Trial: 22529036
Drug: Neurobehavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neurobehavioral intervention (n = 25), weekly sessions
Trial: 22529036
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (n = 13), standard weekly home visits
Trial: 20973982
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 300 μg Q2W or 500 μg Q3W (EDS)
Trial: 20973982
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 150 μg QW (weekly)
Trial: 10323115
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg intravenous injection at induction, followed by 20 mg tablet in the evening of the operation and 20 mg daily from days 2 to 7